ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

Jennifer Woyach, MD
Published: Thursday, Sep 18, 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial, which compared ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma.

Woyach says the study showed that the efficacy of ibrutinib was superior to ofatumumab when given as a single agent. The study also showed response rates were significantly better with ibrutinib [ORR=42.6 vs 4.1% (P <0.0001), ORR+PR with lymphocytosis=62.6 vs 4.1%].

While progression-free survival was not yet reached in the ibrutinib arm, Woyach says the progression-free survival was only about 8 months in the ofatumumab arm.  
Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial, which compared ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma.

Woyach says the study showed that the efficacy of ibrutinib was superior to ofatumumab when given as a single agent. The study also showed response rates were significantly better with ibrutinib [ORR=42.6 vs 4.1% (P <0.0001), ORR+PR with lymphocytosis=62.6 vs 4.1%].

While progression-free survival was not yet reached in the ibrutinib arm, Woyach says the progression-free survival was only about 8 months in the ofatumumab arm.  



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x